FY2024 EPS Estimates for BrainsWay Increased by Analyst

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Analysts at Northland Capmk boosted their FY2024 earnings estimates for BrainsWay in a research note issued to investors on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.06 per share for the year, up from their previous estimate of $0.05. The consensus estimate for BrainsWay's current full-year earnings is $0.05 per share.

BrainsWay (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The business had revenue of $10.50 million during the quarter, compared to analysts' expectations of $10.07 million. BrainsWay had a return on equity of 3.56% and a net margin of 3.88%. During the same quarter in the previous year, the firm posted ($0.01) EPS.

Several other research analysts have also weighed in on BWAY. HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Monday, October 21st. Northland Securities boosted their price target on shares of BrainsWay from $11.00 to $12.50 and gave the stock an "outperform" rating in a research note on Thursday, October 3rd.

BrainsWay Stock Performance

Shares of BWAY stock traded up $0.57 during trading hours on Thursday, reaching $9.61. The company had a trading volume of 64,491 shares, compared to its average volume of 95,747. The stock has a fifty day moving average of $9.19 and a 200-day moving average of $7.45. The company has a market capitalization of $160.28 million, a price-to-earnings ratio of 94.20 and a beta of 1.25. BrainsWay has a 12-month low of $4.16 and a 12-month high of $10.98.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BWAY. Virtu Financial LLC bought a new stake in shares of BrainsWay in the 1st quarter worth about $60,000. Rhumbline Advisers raised its holdings in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock valued at $110,000 after acquiring an additional 1,695 shares during the period. Perritt Capital Management Inc acquired a new position in BrainsWay during the second quarter valued at $121,000. Good Life Advisors LLC increased its holdings in shares of BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock valued at $516,000 after purchasing an additional 22,080 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of BrainsWay by 583.2% during the 1st quarter. Acadian Asset Management LLC now owns 175,416 shares of the company's stock valued at $923,000 after acquiring an additional 149,740 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.